DotBio
Singapore, Singapore· Est.
DotBio creates modular, multi‑specific antibody therapeutics for oncology via its stabilized VH‑domain platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
DotBio creates modular, multi‑specific antibody therapeutics for oncology via its stabilized VH‑domain platform.
OncologyImmunology
Technology Platform
DotBody technology uses stabilized human VH domains derived from a non‑immunogenic germline, enabling rapid assembly of multi‑specific antibody formats and ADCs with high potency and low immunogenicity.
Opportunities
DotBio’s modular platform can accelerate the creation of novel multi‑specific immunotherapies, offering attractive partnership opportunities with pharma companies seeking differentiated oncology candidates.
Risk Factors
Key risks include the lack of disclosed clinical data, potential technical challenges in scaling VH‑domain formats, and intense competition from established bispecific antibody developers.
Competitive Landscape
Competitors such as Genmab, Roche, and Amgen focus on full‑IgG bispecifics; DotBio differentiates through its rapid, modular VH‑domain assembly and Hot‑CoFi stabilization, which may reduce development timelines and manufacturing complexity.